Acacia Pharma has begun a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications. The study is taking place in around 25 centers in the UK, Denmark, Germany and the U.S., and aims to recruit 315 cancer patients receiving highly emetogenic chemotherapy (HEC). The trial compares three doses of AP...